Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Cash from Operations (2020 - 2025)

Maravai Lifesciences Holdings (MRVI) has 6 years of Cash from Operations data on record, last reported at 22768000.0 in Q4 2025.

  • For Q4 2025, Cash from Operations fell 55.54% year-over-year to 22768000.0; the TTM value through Dec 2025 reached 57573000.0, down 871.24%, while the annual FY2025 figure was 57573000.0, 871.24% down from the prior year.
  • Cash from Operations reached 22768000.0 in Q4 2025 per MRVI's latest filing, down from 15150000.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 166221000.0 in Q2 2021 and bottomed at 22768000.0 in Q4 2025.
  • Average Cash from Operations over 5 years is 49033150.0, with a median of 18314000.0 recorded in 2023.
  • Peak YoY movement for Cash from Operations: skyrocketed 1331.09% in 2021, then crashed 287.91% in 2024.
  • A 5-year view of Cash from Operations shows it stood at 58743000.0 in 2021, then soared by 69.1% to 99335000.0 in 2022, then tumbled by 92.16% to 7790000.0 in 2023, then plummeted by 287.91% to 14638000.0 in 2024, then tumbled by 55.54% to 22768000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Operations were 22768000.0 in Q4 2025, 15150000.0 in Q3 2025, and 10265000.0 in Q2 2025.